Lingating, Esterlita .
HRN: 06-81-30 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
04/13/2024
SODIUM FUSIDATE 20MG/G, 15G OINTMENT
04/13/2024
04/19/2024
TOPICAL
20mg/g
TID
Infected Post-op MRM Site
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes